Research
Hormonal
SIRT1 levels in the brain decline with age, leading to cognitive impairment and metabolic dysfunction, while maintaining or increasing SIRT1 activity preserves synaptic plasticity and memory.
Maintaining brain health involves supporting SIRT1 activity, which declines with age. This supports the importance of lifestyle factors (like exercise and caloric restriction) that are known to upregulate SIRT1, potentially preserving memory and synaptic plasticity.
GoodSupportsHIGH confidence
Brain SIRT1 levels are decreased in aged neurons... and are downregulated by a high fat diet... SIRT1-deficient brain had grossly normal anatomy... However, the SIRT1-deficient hippocampus had decreased levels of synaptophysin... and CA1 neurons in these have decreased dendritic spine density.
Why this rating
Supported by knockout mouse studies showing memory deficits and human aging correlations.
Source
SIRT1 in the brain—connections with aging-associated disorders and lifespan
Fanny Ng · Frontiers in Cellular Neuroscience · 2015
DOI 10.3389/fncel.2015.00064
narrative_reviewCited 185×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Brain-specific overexpression of SIRT1 extends lifespan and delays aging phenotypes in mice, primarily through hypothalamic regulation of metabolic homeostasis and circadian rhythms.Good
- SIRT1 activation in the hypothalamus regulates energy metabolism and circadian rhythms, influencing susceptibility to diet-induced obesity and metabolic disorders.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →